gamma-aminobutyric acid has been researched along with Kidney Failure, Chronic in 38 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pregabalin is an effective alternative for treatment of uraemic pruritus." | 9.20 | Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. ( Jiao, S; Meng, J; Ren, W; Xiao, Y; Yue, J; Zhao, T, 2015) |
| " Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN." | 9.17 | Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013) |
| "Gabapentin is an effective agent in treating uremic pruritus." | 9.14 | Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009) |
| "Our study shows that gabapentin is safe and effective for treating uraemic pruritus in haemodialysis patients." | 9.11 | Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004) |
| "We evaluated the effect of pregabalin in the treatment of uraemic pruritus not due to secondary hyperparathyroidism." | 7.76 | The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. ( Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A, 2010) |
| "We describe a 60-year-old woman who became comatose after a single dose of gabapentin for right-sided sciatalgia." | 7.73 | Gabapentin-induced coma in a patient with renal failure. ( Aygen, B; Bektas, S; Berilgen, MS; Dag, S; Dogukan, A; Gunal, AI, 2006) |
| "Pruritus is common among patients with end-stage renal disease undergoing dialysis, and the pathogenesis can be explained by several mechanisms." | 6.80 | Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. ( Jiao, S; Meng, J; Ren, W; Xiao, Y; Yue, J; Zhao, T, 2015) |
| "Ondansetron has negligible effect on uremic pruritus and is expensive." | 6.80 | Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. ( Jiao, S; Meng, J; Ren, W; Xiao, Y; Yue, J; Zhao, T, 2015) |
| "Pruritus is a common and bothersome problem in 30-50% of hemodialysis patients." | 6.74 | Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009) |
| "Gabapentin is an effective agent in treating uremic pruritus." | 6.74 | Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009) |
| "Uraemic pruritus is a common and distressing symptom in patients on haemodialysis for chronic renal failure." | 6.71 | Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004) |
| "Gabapentin or placebo were administered thrice weekly, at the end of haemodialysis sessions." | 6.71 | Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004) |
| "Gabapentin is an anticonvulsant that alleviates neuropathic pain." | 6.71 | Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004) |
| "Uraemic pruritus is a common and distressing symptom in patients undergoing haemodialysis." | 5.36 | The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. ( Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A, 2010) |
| "Pregabalin is an effective alternative for treatment of uraemic pruritus." | 5.20 | Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. ( Jiao, S; Meng, J; Ren, W; Xiao, Y; Yue, J; Zhao, T, 2015) |
| " Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN." | 5.17 | Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013) |
| "Gabapentin is an effective agent in treating uremic pruritus." | 5.14 | Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009) |
| "Our study shows that gabapentin is safe and effective for treating uraemic pruritus in haemodialysis patients." | 5.11 | Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004) |
| "Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak." | 4.95 | Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017) |
| "We evaluated the effect of pregabalin in the treatment of uraemic pruritus not due to secondary hyperparathyroidism." | 3.76 | The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. ( Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A, 2010) |
| "We describe a 60-year-old woman who became comatose after a single dose of gabapentin for right-sided sciatalgia." | 3.73 | Gabapentin-induced coma in a patient with renal failure. ( Aygen, B; Bektas, S; Berilgen, MS; Dag, S; Dogukan, A; Gunal, AI, 2006) |
| "Gabapentin is an antiepileptic medication that also has been used for restless legs syndrome." | 3.73 | Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. ( Lavoie, S; Lipson, J; Zimmerman, D, 2005) |
| "To study the pharmacokinetics of vigabatrin in a patient affected with tuberous sclerosis who developed major agitation and aggression, while receiving vigabatrin orally (1." | 3.69 | Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ( Chiron, C; Guillonneau, M; Jacqz-Aigrain, E; Loirat, C; Macher, MA; Montes, C; Rey, E, 1997) |
| "Ondansetron has negligible effect on uremic pruritus and is expensive." | 2.80 | Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. ( Jiao, S; Meng, J; Ren, W; Xiao, Y; Yue, J; Zhao, T, 2015) |
| "Pruritus is common among patients with end-stage renal disease undergoing dialysis, and the pathogenesis can be explained by several mechanisms." | 2.80 | Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. ( Jiao, S; Meng, J; Ren, W; Xiao, Y; Yue, J; Zhao, T, 2015) |
| "The objective of this study was to describe a population pharmacokinetic analysis of gabapentin enacarbil in patients with varying degrees of renal function, using data from an open-label study of gabapentin enacarbil in patients with renal impairment (XenoPort, Inc." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| " Pharmacokinetic data were compared with those from Phase I-III studies in subjects with normal renal function to evaluate the relationship between gabapentin oral clearance (CL/F) and CrCL." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| " Based on the population pharmacokinetic analysis, gabapentin CL/F after administration of gabapentin enacarbil was proportionally related to CrCL, with an approximately 1." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| " protocol XP066), to determine whether dosage adjustments are necessary in patients with renal impairment." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| "The data suggest that dosage adjustment for gabapentin enacarbil is necessary in patients with impaired renal function." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| "Gabapentin is an effective agent in treating uremic pruritus." | 2.74 | Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009) |
| "Pruritus is a common and bothersome problem in 30-50% of hemodialysis patients." | 2.74 | Gabapentin and uremic pruritus in hemodialysis patients. ( Eskandari, D; Ganji, MR; Khashayar, P; Meysamie, AP; Razeghi, E; Togha, M, 2009) |
| "Gabapentin or placebo were administered thrice weekly, at the end of haemodialysis sessions." | 2.71 | Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004) |
| "Uraemic pruritus is a common and distressing symptom in patients on haemodialysis for chronic renal failure." | 2.71 | Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004) |
| "Gabapentin is an anticonvulsant that alleviates neuropathic pain." | 2.71 | Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. ( Celiker, H; Gunal, AI; Gunal, SY; Kirciman, E; Ozalp, G; Yoldas, TK, 2004) |
| "Uremic pruritus is a common and burdensome symptom afflicting patients with advanced chronic kidney disease (CKD) and has been declared a priority for CKD research by patients." | 2.55 | Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017) |
| "RLS in end-stage renal disease (ESRD) patients is especially problematic due to premature discontinuation of dialysis and increased mortality." | 2.55 | Clinical management of restless legs syndrome in end-stage renal disease patients. ( Jo, J; Mousa, SA; Sahli, ZT; Tarazi, FI, 2017) |
| "Any intervention for the treatment of uremic pruritus was included." | 2.55 | Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017) |
| " With 2-L exchanges every 2 hours, we document an apparent elimination half-life of 41." | 1.46 | Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance. ( Edwards, JC; Ibrahim, H; Oman, Z; Schuelke, M, 2017) |
| " Patients with chronic kidney disease often receive inappropriately high gabapentin dosage for their kidney function, occasioning overt toxicity; advanced age and comorbidity predispose these patients for toxicity." | 1.36 | Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. ( McKian, KP; Qian, Q; Zand, L, 2010) |
| "Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression." | 1.36 | Osseous metaplasia late in the course of nephrogenic systemic fibrosis. ( Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ, 2010) |
| "8%); toxic manifestations were more severe in group III than in group II." | 1.36 | Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. ( McKian, KP; Qian, Q; Zand, L, 2010) |
| "Gabapentin toxicity was suspected initially in only 41." | 1.36 | Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. ( McKian, KP; Qian, Q; Zand, L, 2010) |
| "Uraemic pruritus is a common and distressing symptom in patients undergoing haemodialysis." | 1.36 | The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. ( Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A, 2010) |
| "The U." | 1.35 | Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. ( Iloanya, PC; Nye, D; Onuigbo, MA, 2009) |
| " Its normal plasma half-life is 2 - 3 hours; dosage modifications are obligatory in renal insufficiency." | 1.35 | Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. ( Iloanya, PC; Nye, D; Onuigbo, MA, 2009) |
| "Pregabalin is prescribed for neuropathic pain." | 1.35 | Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure. ( Goldfarb, DS; Hoffman, RS; Matalon, D; Yoo, L, 2009) |
| "GBP increases the risk of myoclonus in ESRD." | 1.33 | Gabapentin-induced myoclonus in end-stage renal disease. ( Bell, WL; Glenn, DG; O'Donovan, CA; Zhang, C, 2005) |
| "Three of 71 patients had myoclonus with GBP doses ranging from 9 mg/kg to 20 mg/kg and within 4 months of treatment onset." | 1.33 | Gabapentin-induced myoclonus in end-stage renal disease. ( Bell, WL; Glenn, DG; O'Donovan, CA; Zhang, C, 2005) |
| "Myoclonus was characterized as multifocal, involving all extremities in the three patients." | 1.33 | Gabapentin-induced myoclonus in end-stage renal disease. ( Bell, WL; Glenn, DG; O'Donovan, CA; Zhang, C, 2005) |
| "Gabapentin is an antiepileptic medication that also has been used for restless legs syndrome." | 1.33 | Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. ( Lavoie, S; Lipson, J; Zimmerman, D, 2005) |
| "Vigabatrin is an irreversible inhibitor of GABA-transaminase, effective in the treatment of drug-resistant epilepsy and reported to be eliminated unchanged by renal excretion." | 1.30 | Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ( Chiron, C; Guillonneau, M; Jacqz-Aigrain, E; Loirat, C; Macher, MA; Montes, C; Rey, E, 1997) |
| " A pharmacokinetic study of the S(+) and R(-) enantiomers of vigabatrin was performed before and during dialysis." | 1.30 | Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ( Chiron, C; Guillonneau, M; Jacqz-Aigrain, E; Loirat, C; Macher, MA; Montes, C; Rey, E, 1997) |
| " Although vigabatrin is known to have stereoselective kinetics, the difference in plasma dry concentrations and pharmacokinetics of the S(+) and R(-) enantiomers that we observed during long term administration at high doses in a patient with impaired renal function, has not been reported before." | 1.30 | Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ( Chiron, C; Guillonneau, M; Jacqz-Aigrain, E; Loirat, C; Macher, MA; Montes, C; Rey, E, 1997) |
| "Pyridoxal phosphate contents were substantially reduced in brains of the hemodialyzed patients, but metabolites of noradrenaline, 3,4-dihydroxyphenylethylamine (dopamine), and 5-hydroxytryptamine (serotonin) were present in normal amounts." | 1.27 | Neurochemical abnormalities in brains of renal failure patients treated by repeated hemodialysis. ( Foulks, JG; Godolphin, WJ; Ito, M; Kish, SJ; Perry, TL; Sweeney, VP; Yong, VW, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (13.16) | 18.7374 |
| 1990's | 2 (5.26) | 18.2507 |
| 2000's | 17 (44.74) | 29.6817 |
| 2010's | 14 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, H | 1 |
| Oman, Z | 1 |
| Schuelke, M | 1 |
| Edwards, JC | 1 |
| Simonsen, E | 1 |
| Komenda, P | 1 |
| Lerner, B | 1 |
| Askin, N | 1 |
| Bohm, C | 1 |
| Shaw, J | 1 |
| Tangri, N | 1 |
| Rigatto, C | 1 |
| Reszke, R | 1 |
| Szepietowski, JC | 1 |
| Yue, J | 1 |
| Jiao, S | 1 |
| Xiao, Y | 1 |
| Ren, W | 1 |
| Zhao, T | 1 |
| Meng, J | 1 |
| Shea, YF | 1 |
| Mok, MM | 1 |
| Chang, RS | 1 |
| Beladi Mousavi, SS | 1 |
| Zeraati, A | 1 |
| Moradi, S | 1 |
| Mousavi, MB | 1 |
| Mettang, T | 1 |
| Sahli, ZT | 1 |
| Jo, J | 1 |
| Mousa, SA | 1 |
| Tarazi, FI | 1 |
| Razeghi, E | 1 |
| Eskandari, D | 1 |
| Ganji, MR | 1 |
| Meysamie, AP | 1 |
| Togha, M | 1 |
| Khashayar, P | 1 |
| Yoo, L | 1 |
| Matalon, D | 1 |
| Hoffman, RS | 1 |
| Goldfarb, DS | 1 |
| Healy, DG | 1 |
| Ingle, GT | 1 |
| Brown, P | 1 |
| Mansfield, AS | 1 |
| Qian, Q | 2 |
| Onuigbo, MA | 1 |
| Nye, D | 1 |
| Iloanya, PC | 1 |
| Zand, L | 1 |
| McKian, KP | 1 |
| Berk, DR | 1 |
| Miller, A | 1 |
| Scarlett, D | 1 |
| Wippold, FJ | 1 |
| Bayliss, SJ | 1 |
| Lu, D | 1 |
| Aperis, G | 1 |
| Paliouras, C | 1 |
| Zervos, A | 1 |
| Arvanitis, A | 1 |
| Alivanis, P | 1 |
| Prieto-Pérez, L | 1 |
| Montastruc, J | 1 |
| García-Ruiz, PJ | 1 |
| Lal, R | 1 |
| Sukbuntherng, J | 1 |
| Luo, W | 1 |
| Chen, D | 1 |
| Blumenthal, R | 1 |
| Ho, J | 1 |
| Cundy, KC | 1 |
| Biyik, Z | 1 |
| Solak, Y | 1 |
| Atalay, H | 1 |
| Gaipov, A | 1 |
| Guney, F | 1 |
| Turk, S | 1 |
| Penumalee, S | 1 |
| Kissner, PZ | 1 |
| Migdal, SD | 1 |
| Micozkadioglu, H | 1 |
| Ozdemir, FN | 1 |
| Kut, A | 1 |
| Sezer, S | 1 |
| Saatci, U | 1 |
| Haberal, M | 1 |
| Gunal, AI | 2 |
| Ozalp, G | 1 |
| Yoldas, TK | 1 |
| Gunal, SY | 1 |
| Kirciman, E | 1 |
| Celiker, H | 1 |
| Zhang, C | 1 |
| Glenn, DG | 1 |
| Bell, WL | 1 |
| O'Donovan, CA | 1 |
| Lipson, J | 1 |
| Lavoie, S | 1 |
| Zimmerman, D | 1 |
| Molnar, MZ | 1 |
| Novak, M | 1 |
| Mucsi, I | 1 |
| Dogukan, A | 1 |
| Aygen, B | 1 |
| Berilgen, MS | 1 |
| Dag, S | 1 |
| Bektas, S | 1 |
| Sasaki, S | 1 |
| Yokozawa, T | 1 |
| Cho, EJ | 1 |
| Oowada, S | 1 |
| Kim, M | 1 |
| Kosmadakis, GC | 1 |
| Zerefos, N | 1 |
| Elias, AN | 1 |
| Pahl, M | 1 |
| Stone, S | 1 |
| Vaziri, ND | 1 |
| Valenta, LJ | 1 |
| Bachmann, D | 1 |
| Ritz, R | 1 |
| Wad, N | 1 |
| Haefeli, WE | 1 |
| Jacqz-Aigrain, E | 1 |
| Guillonneau, M | 1 |
| Rey, E | 1 |
| Macher, MA | 1 |
| Montes, C | 1 |
| Chiron, C | 1 |
| Loirat, C | 1 |
| Belgrade, M | 1 |
| Bassilios, N | 1 |
| Launay-Vacher, V | 1 |
| Khoury, N | 1 |
| Rondeau, E | 1 |
| Deray, G | 1 |
| Sraer, JD | 1 |
| Jones, H | 1 |
| Aguila, E | 1 |
| Farber, HW | 1 |
| Perry, TL | 2 |
| Yong, VW | 1 |
| Kish, SJ | 2 |
| Ito, M | 1 |
| Foulks, JG | 1 |
| Godolphin, WJ | 2 |
| Sweeney, VP | 2 |
| Price, JD | 1 |
| Reeve, CE | 1 |
| Minuk, GY | 1 |
| Winder, A | 1 |
| Burgess, ED | 1 |
| Sarjeant, EJ | 1 |
| Valovicová, E | 1 |
| Spustová, V | 1 |
| Dzúrik, R | 1 |
| Cernácek, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus[NCT04650750] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Prospective Randomized Study Evaluating the Efficacy of the Spherical Absorptive Carbon AST-120 in Hemodialysis Patients With Uremic Pruritus..[NCT04639674] | Phase 4 | 100 participants (Actual) | Interventional | 2020-07-02 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
5 reviews available for gamma-aminobutyric acid and Kidney Failure, Chronic
| Article | Year |
|---|---|
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
End-Stage Renal Disease Chronic Itch and Its Management.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antipruritics; Chronic Disease; Cyclohexanecarboxylic A | 2018 |
Uremic Itch Management.
Topics: Acupuncture Therapy; Amines; Analgesics, Opioid; Anticonvulsants; Calcineurin Inhibitors; Cyclohexan | 2016 |
Clinical management of restless legs syndrome in end-stage renal disease patients.
Topics: Amines; Analgesics, Opioid; Benzodiazepines; Benzothiazoles; Comorbidity; Cyclohexanecarboxylic Acid | 2017 |
Management of restless legs syndrome in patients on dialysis.
Topics: Amines; Anticonvulsants; Benzothiazoles; Clonazepam; Cyclohexanecarboxylic Acids; Dopamine Agents; G | 2006 |
7 trials available for gamma-aminobutyric acid and Kidney Failure, Chronic
| Article | Year |
|---|---|
Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study.
Topics: Adult; Aged; Analgesics; Antipruritics; Double-Blind Method; Drug Therapy, Combination; Female; gamm | 2015 |
The effect of gabapentin on muscle cramps during hemodialysis: A double-blind clinical trial.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gamma | 2015 |
Gabapentin and uremic pruritus in hemodialysis patients.
Topics: Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gaba | 2009 |
Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Topics: Administration, Oral; Adult; Aged; Analgesics; Anticonvulsants; Biomarkers; Biotransformation; Carba | 2012 |
Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial.
Topics: Amines; Anti-Anxiety Agents; Calcium Channel Blockers; Cross-Over Studies; Cyclohexanecarboxylic Aci | 2013 |
Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study.
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dopamine Agonists; Female; Gabapentin; | 2004 |
Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans | 2004 |
26 other studies available for gamma-aminobutyric acid and Kidney Failure, Chronic
| Article | Year |
|---|---|
Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Diabetic Neuropathies; Fema | 2017 |
Gabapentin-induced myoclonus in an elderly with end-stage renal failure.
Topics: Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2014 |
Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure.
Topics: Adult; Analgesics; Dose-Response Relationship, Drug; Female; gamma-Aminobutyric Acid; Humans; Kidney | 2009 |
Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; K | 2009 |
71-year-old man with chronic kidney failure and sudden change of mental status.
Topics: Academic Medical Centers; Aged; Amines; Analgesics; Confusion; Cyclohexanecarboxylic Acids; Dose-Res | 2009 |
Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients.
Topics: Acyclovir; Aged; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 2009 |
Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity.
Topics: Adult; Age Distribution; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; g | 2010 |
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxy | 2010 |
The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antipruritics; Central Nervous System Agents; Female; ga | 2010 |
[Myoclonias secondary to gabapentin in a patient with chronic renal failure].
Topics: Aged; Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Kidney Failu | 2011 |
Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient.
Topics: Acetates; Amines; C-Peptide; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Aci | 2003 |
Gabapentin-induced myoclonus in end-stage renal disease.
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2005 |
Gabapentin-induced myopathy in 2 patients on short daily hemodialysis.
Topics: Adult; Amines; Anticonvulsants; Atorvastatin; Calcium Channels; Comorbidity; Cyclohexanecarboxylic A | 2005 |
Gabapentin-induced coma in a patient with renal failure.
Topics: Administration, Oral; Amines; Coma; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; F | 2006 |
Protective role of gamma-aminobutyric acid against chronic renal failure in rats.
Topics: Administration, Oral; Albuminuria; Animals; Antioxidants; Blood Pressure; Catalase; Creatinine; Dose | 2006 |
Uremic pruritus.
Topics: Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Capsaicin; Cyclohexanecarboxylic Acids; Gabape | 2006 |
Modulatory role of gamma-aminobutyric acid (GABA) in the regulation of gonadotropin secretion in patients with chronic renal failure.
Topics: Adult; Estradiol; Female; Follicle Stimulating Hormone; gamma-Aminobutyric Acid; Gonadotropin-Releas | 1982 |
Vigabatrin dosing during haemodialysis.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Monitoring; Epilepsy, Complex Partial; gamma | 1996 |
Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure.
Topics: Adult; Anticonvulsants; Enzyme Inhibitors; gamma-Aminobutyric Acid; Humans; Kidney Failure, Chronic; | 1997 |
Postherpetic pain control with concomitant illness?
Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Biological Availability; | 2001 |
Gabapentin neurotoxicity in a chronic haemodialysis patient.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Epilepsy, Absence; | 2001 |
Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Overdose; Female; Gabapentin; g | 2002 |
Neurochemical abnormalities in brains of renal failure patients treated by repeated hemodialysis.
Topics: Adult; Aluminum; Amino Acids; Brain; Brain Chemistry; Choline O-Acetyltransferase; gamma-Aminobutyri | 1985 |
Brain gamma-aminobutyric acid deficiency in dialysis encephalopathy.
Topics: Adult; Aluminum; Brain Chemistry; Brain Diseases; Cerebral Cortex; Choline O-Acetyltransferase; gamm | 1985 |
Serum gamma-aminobutyric acid (GABA) levels in patients with hepatic encephalopathy.
Topics: Ammonia; Chronic Disease; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Kidney Failure, C | 1985 |
The utilization of glucose in the brain slices during uraemia.
Topics: Ammonia; Animals; Aspartic Acid; Blood Proteins; Brain; Cerebral Cortex; gamma-Aminobutyric Acid; Gl | 1974 |